ストックスクリーナーアプリを入手
184.49
1.70%
3.0321
Biogen Inc (BIIB) 最新ニュース
Biogen Inc. Stock Stifel CNS Forum: $190 Target Price Driven by Tau Pipeline Pivot - TIKR.com
Biogen (BIIB) Valuation Check As New Lecanemab Persistence Data Support Alzheimer’s Franchise Potential - simplywall.st
Results from Real-World, Long-Term Treatment Persistence with LEQEMBI(R) (lecanemab-irmb) in the United States Presented at AD/PD(TM) 2026 - ACN Newswire
Swiss Life Asset Management Ltd Sells 21,970 Shares of Biogen Inc. $BIIB - MarketBeat
Biogen Inc. stock outperforms competitors on strong trading day - MSN
How Class Action Risks and Lupus Drug Advances Could Reframe Biogen's (BIIB) Innovation Narrative - simplywall.st
Biogen Inc. stock underperforms Friday when compared to competitors - MarketWatch
Lecanemab shows 67% patient retention at 24 months in US study - Investing.com
Why Biogen Inc. (BIIB) is a top value stock for the long term - MSN
Biogen Inc. stock gains momentum from pipeline advances and analyst upgrades amid biotech recovery - AD HOC NEWS
BIIB: High Persistence of Lecanemab Treatment in Real-World Anal - GuruFocus
Biogen unveils real-world data on early Alzheimer treatment persistence in U.S. - Traders Union
Eisai and Biogen Report High Treatment Persistence for Lecanemab in Real-World Alzheimer's Patients - Quiver Quantitative
Eli Lilly, Biogen/Eisai win UK review for use of Alzheimer’s drugs in NHS - MSN
Amyotrophic Lateral Sclerosis Market: Strong Pharma Growth Forecast Through 2034 – DelveInsight | Helixmith, Sanofi, Denali Therapeutics, Transposon Therapeutics, GSK, Biogen, Ionis Pharmaceuticals - Barchart
Eli Lilly (LLY) and Biogen (BIIB) Alzheimer's Drug Review by UK Watchdog - GuruFocus
U.K. to review use of Alzheimer’s drugs in NHS (LLY:NYSE) - Seeking Alpha
Neuromuscular Disease Therapeutics Market to Reach US$45.62 - openPR.com
England to Review Rejection of Alzheimer’s Drugs for NHS - Bloomberg.com
PSA Biogas Upgrading Market Is Going to Boom | Biogen • Xebec Adsorption Inc. • Aqualia - openPR.com
Farmers Trust Co. Increases Holdings in Biogen Inc. $BIIB - MarketBeat
Biogen Inc. $BIIB Stake Raised by AIA Group Ltd - MarketBeat
Biogen’s BIIB080 Imaging Study Completes, Marking Quiet but Key Step in Alzheimer’s Pipeline - TipRanks
Biogen Targets Pediatric MS Growth With New Phase 3 Fumarate Study - TipRanks
Biogen to present litifilimab data for cutaneous lupus at AAD - Investing.com
Securities Litigation on Behalf of Purchasers of Biogen, Inc. Securities (BIIB) Certified as Class Action - marketscreener.com
Securities Litigation on Behalf of Purchasers of Biogen, Inc. Securities (BIIB) Certified as Class Action - GlobeNewswire Inc.
Biogen to Present New Late-Breaking Litifilimab Phase 2 AMETHYST Data in Cutaneous Lupus Erythematosus at 2026 American Academy of Dermatology Annual Meeting - Biogen
The Escalator: Biogen, Flagship Pioneering, Grail and more - Medical Marketing and Media
Insight Wealth Strategies LLC Buys Shares of 28,960 Biogen Inc. $BIIB - MarketBeat
Biogen Inc. $BIIB Shares Sold by Hudson Bay Capital Management LP - MarketBeat
Biogen Conference: Tau ASO CELIA Updates, Pre-Symptomatic Leqembi, SMA Phase 3 Plans - Yahoo Finance
Biogen Inc. stock underperforms Wednesday when compared to competitors - MarketWatch
Here's why Biogen Inc. (BIIB) is a strong momentum stock - MSN
Biogen at Stifel Forum: Strategic Insights on Alzheimer’s and Neuromuscular Advances - Investing.com
BIIB: Advances in Alzheimer's, SMA, and immunology pipelines highlight innovation and pivotal trials - TradingView
Biogen Inc. (NASDAQ: BIIB) Q4 2025 earnings call transcript - MSN
HSBC Maintains Reduce Rating for BIIB, Raises Price Target | BII - GuruFocus
Biogen (NASDAQ:BIIB) Stock Price Expected to Rise, HSBC Analyst Says - MarketBeat
Biogen Legal Chief Exit Puts Focus On Valuation Gap And Returns - simplywall.st
Biogen (BIIB) Valuation Check As New SMA Data And Phase 3 Plans Draw Fresh Growth Focus - Yahoo Finance
Dow Update: Is Biogen Inc showing insider buying2026 Breakouts & Fast Momentum Entry Tips - baoquankhu1.vn
Gotham Asset Management Boosts Biogen Stake by 65% - National Today
Gotham Asset Management LLC Has $37.89 Million Position in Biogen Inc. $BIIB - MarketBeat
Biogen Stock Holdings Boosted by Brevan Howard - National Today
Biogen Inc. $BIIB Stock Holdings Boosted by Brevan Howard Capital Management LP - MarketBeat
Behavioral Patterns of BIIB and Institutional Flows - Stock Traders Daily
Banco Bilbao Vizcaya Argentaria S.A. Increases Stake in Biogen Inc. $BIIB - MarketBeat
Capula Management Ltd Takes $1.43 Million Position in Biogen Inc. $BIIB - MarketBeat
Cinctive Capital Management LP Raises Stake in Biogen Inc. $BIIB - MarketBeat
What makes Biogen (BIIB) an attractive long-term holding? - MSN
Suvretta Capital Management LLC Has $23.56 Million Stake in Biogen Inc. $BIIB - MarketBeat
iSAM Funds UK Ltd Has $2.41 Million Stock Holdings in Biogen Inc. $BIIB - MarketBeat
Does New Once-Yearly SMA Data And Phase 3 Plan Change The Bull Case For Biogen (BIIB)? - simplywall.st
Biogen CLO Retiring After 20 Years With Biopharma Biz - Law360
Biogen's Legal Chief for 2 Decades Exiting in May - Law.com
Legal & General Group Plc Buys 146,583 Shares of Biogen Inc. $BIIB - MarketBeat
BIIB Stock Price, Quote & Chart | BIOGEN INC (NASDAQ:BIIB) - ChartMill
Assessing Biogen (BIIB) Valuation After Recent Shareholder Return Momentum - Sahm
Biogen Details West Coast Hub, Felzartamab Phase 3 Plans and AMR Readout Timeline at Conference - Yahoo Finance
Biogen Rare Disease Data And Valuation Discount Draw Investor Attention - Yahoo Finance
Johnson Fistel, PLLP Investigates Claims on Behalf of - GlobeNewswire
MDA 2026: Biogen, Sarepta, Edgewise Address Muscle Disorders - BioSpace
Biogen’s Spinraza successor benefits SMA patients unresponsive to gene therapy - Yahoo
Swiss National Bank Cuts Stake in Biogen Inc. $BIIB - MarketBeat
Biogen Inc. Announces Departure of Chief Legal Officer Susan H. Alexander Effective May 2026 - Minichart
Biogen Inc. $BIIB Shares Sold by Dimensional Fund Advisors LP - MarketBeat
Biogen presents Phase 1b data on salanersen for SMA treatment - Investing.com South Africa
0.46%
1.16%
大文字化:
|
ボリューム (24 時間):